This modification results in a poorer overall 8-year disease-free survival and overall survival, except that the patients with ETV6-RUNX1-positive ALL or age of 1 to 6 years are equally well in both treatment arms. Here, RUNX1 is linked to acute lymphoblastic leukemia.